CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: selinexor
Accession: CHEBI:229764
browse the term
Definition: A member of the class of triazoles that is 1H-1,2,4-triazole substituted by (1Z)-3-oxo-3-[2-(pyrazin-2-yl)hydrazinyl]prop-1-en-1-yl and 3,5-bis(trifluoromethyl)phenyl groups at positions 1 and 3, respectively. It is a prescription medicine approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Synonyms: related_synonym: (2Z)-3-{3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1- yl}-N'-(pyrazin-2-yl)prop-2-enehydrazide; Formula=C17H11F6N7O; InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-; InChIKey=DEVSOMFAQLZNKR-RJRFIUFISA-N; KPT 330; SMILES=FC(F)(F)C1=CC(=CC(=C1)C1=NN(\\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F; Xpovio; selinexorum
xref: DrugBank:DB11942; HMDB:HMDB0258217; KEGG:D11222
xref_mesh: MESH:C585161
xref: PMID:23373539; PMID:27893412; PMID:28314790; PMID:28810913; PMID:28852098; PMID:29707241; PMID:30064906; PMID:30115935; PMID:30996012; PMID:32598257; PMID:33403670; PMID:33507295; PMID:33601919; PMID:34488662; PMID:34669417; PMID:34741230; PMID:35355406; PMID:35477814; PMID:35667526; PMID:35941226; PMID:36180918; PMID:36200270; PMID:36622814; PMID:36731340; PMID:36827679; PMID:36847599; PMID:37016732; PMID:37046649; PMID:37047788; PMID:37079389; PMID:37094850; PMID:37126200; PMID:37175668; PMID:37184196; PMID:37191210; PMID:37346402; PMID:37595020; PMID:37715291; PMID:37760508; PMID:37945593; PMID:38105606; PMID:38186637; PMID:38454813; Wikipedia:Selinexor
G
Atm
ATM serine/threonine kinase
multiple interactions
ISO
[selinexor co-treated with INCB057643] results in decreased phosphorylation of ATM protein
CTD
PMID:37899423
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
G
Atr
ATR serine/threonine kinase
multiple interactions
ISO
[selinexor co-treated with INCB057643] results in decreased phosphorylation of ATR protein
CTD
PMID:37899423
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
G
Bbc3
Bcl-2 binding component 3
multiple interactions increases expression
ISO
[INCB057643 co-treated with selinexor] results in increased expression of BBC3 protein selinexor results in increased expression of BBC3 protein
CTD
PMID:37899423
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
G
Chek1
checkpoint kinase 1
multiple interactions
ISO
[selinexor co-treated with INCB057643] results in decreased phosphorylation of CHEK1 protein
CTD
PMID:37899423
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
G
Chek2
checkpoint kinase 2
multiple interactions
ISO
[selinexor co-treated with INCB057643] results in decreased phosphorylation of CHEK2 protein
CTD
PMID:37899423
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
G
H2ax
H2A.X variant histone
increases expression multiple interactions
ISO
selinexor results in increased expression of H2AX protein [selinexor co-treated with INCB057643] results in increased expression of H2AX protein
CTD
PMID:37899423
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
G
Mdm2
MDM2 proto-oncogene
increases expression multiple interactions
ISO
selinexor results in increased expression of MDM2 protein [INCB057643 co-treated with selinexor] results in increased expression of MDM2 protein
CTD
PMID:37899423
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
G
Myc
MYC proto-oncogene, bHLH transcription factor
multiple interactions decreases expression
ISO
INCB057643 promotes the reaction [selinexor results in decreased expression of MYC mRNA]; INCB057643 promotes the reaction [selinexor results in decreased expression of MYC protein]; selinexor promotes the reaction [INCB057643 results in decreased expression of MYC mRNA]; selinexor promotes the reaction [INCB057643 results in decreased expression of MYC protein] selinexor results in decreased expression of MYC mRNA; selinexor results in decreased expression of MYC protein
CTD
PMID:37899423
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
G
Pmaip1
phorbol-12-myristate-13-acetate-induced protein 1
multiple interactions
ISO
[INCB057643 co-treated with selinexor] results in increased expression of PMAIP1 protein
CTD
PMID:37899423
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
G
Tp53
tumor protein p53
increases expression multiple interactions
ISO
selinexor results in increased expression of TP53 protein [INCB057643 co-treated with selinexor] results in increased expression of TP53 protein
CTD
PMID:37899423
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Tp73
tumor protein p73
increases expression
ISO
selinexor results in increased expression of TP73 protein
CTD
PMID:37899423
NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128
G
Wee1
WEE1 G2 checkpoint kinase
multiple interactions
ISO
[selinexor co-treated with INCB057643] results in decreased phosphorylation of WEE1 protein
CTD
PMID:37899423
NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all